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This guideline was compiled according to the British Society
of Haematology (BSH) process at https://b-s-h.org.uk/guide
lines/proposing-and-writing-a-new-bsh-guideline/. The Grad-
ing of Recommendations Assessment, Development and
Evaluation (GRADE) nomenclature was used to evaluate
levels of evidence and to assess the strength of recommenda-
tions. The GRADE criteria can be found at http://www.grade
workinggroup.org
Literature review details
This BSH guideline was developed and updated from a pre-
vious Royal College of Obstetricians and Gynaecologists
(RCOG) Green-top guideline1 in accordance with the stan-
dard method of producing BSH guidelines. Medline, Embase,
the Cochrane Database of Systematic Reviews, the Cochrane
Control Register of Controlled Trials (CONTROL), the Data-
base of Abstracts of Reviews and Effects (DARE), the ACP
Journal Club and the Ovid database were searched for rele-
vant randomised controlled trials, systematic reviews and
meta-analyses between 2000 and August 2018. In all, 218
papers were identified. Search terms included: ‘sickle cell’,
‘hydroxycarbamide’, ‘antenatal’, ‘pregnancy’, ‘intrapartum’,
‘penicillin prophylaxis’, ‘ACE inhibitor’, ‘transfusion’, ‘ultra-
sound’, ‘Doppler’, ‘echocardiogram’, ‘anti-coagulation’, ‘pro-
phylaxis’, ‘sickle cell and risk factors’, ‘preconceptual’ and
‘sickle cell crisis’ and included all relevant Medical Subject
Headings (MeSH) terms and subheadings. The search was
limited to humans and the English language. The National
Library for Health and the National Guidelines Clearing
House were also searched for relevant guidelines.
Review of the manuscript
Review of the manuscript was performed by the BSH Guide-
lines Committee, General Haematology Task Force, the BSH
Guidelines Committee and the members of the sounding
board of BSH. It was also placed on the members’ section of
the BSH website for comment. It has also been reviewed by
the Royal College of Obstetricians and Gynaecologists, Sickle
Cell Society and BSH Obstetric Haematology Special Interest
Group; these organisations do not necessarily approve or
endorse the contents.
Introduction
The purpose of this guideline is to describe the management
of sickle cell disease (SCD) in pregnancy in the UK. It will
cover preconception screening and antenatal, intrapartum
and postnatal management of women with the condition. It
will not cover the management of women with sickle cell
trait. Updates from the previous guideline1 include new
information on pre-implantation genetic diagnosis (PGD),
more comprehensive information on pre-conceptual screen-
ing and medication review, updated information on throm-
boprophylaxis, aspirin and vitamin D, changes to advice on
antenatal care including frequency of ultrasonography (USS)
scanning. It also includes reference to the most recent
National Institute for Health and Clinical Excellence (NICE)
and RCOG guidelines. SCD comprises a group of conditions
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caused by the inheritance of the abnormal haemoglobin
sickle gene (HbS). The most severe form of SCD is homozy-
gous SCD (HbSS) but SCD can also be due to compound
heterozygous genotypes of HbS and another haemoglobin
variant (e.g., HbC, HbDPunjab, HbE or b thalassaemia, see
Table I).
Sickle cell disease is one of the most common inherited
condition worldwide, with over 300 000 children born with
the condition each year globally, three-quarters of whom are
born in Africa.3 The prevalence of SCD varies considerably
across different ethnic communities, predominantly affecting
people of African or African–Caribbean origin. Owing to
population migration, SCD is now of increasing importance
worldwide and there are increasing numbers of affected indi-
viduals in Europe and the United States. Within Europe, the
UK has the largest population with the condition. In the UK
it is estimated that there are 15 000 affected individuals, and
approximately 300 infants born with the condition each year.
The pathophysiology of SCD is the consequence of poly-
merisation of the abnormal sickle haemoglobin in low oxy-
gen conditions leading to the formation of rigid and fragile
sickle-shaped red cells. These cells are prone to increased
breakdown, which causes haemolytic anaemia and the sickle-
shaped red cells do not flow through blood vessels easily,
causing blockage (vaso-occlusion) in small vessels, leading to
most of the clinical features, including acute painful crises.
Other complications of SCD include acute chest syndrome,
pulmonary hypertension (PH), stroke, renal dysfunction,
retinal disease, leg ulcers, cholelithiasis and avascular necro-
sis. SCD was previously associated with high childhood mor-
tality, but now, in high-resource countries with neonatal
screening and lifelong treatment, life expectancy is at least
the mid-50s. With the majority of individuals born with
SCD in the UK living to reproductive age and beyond, man-
agement of this condition in pregnancy is now more perti-
nent.
There are approximately 110–200 pregnancies in women
with SCD per year in the UK.4 Pregnancy in women with
SCD is associated with higher risk of mortality and morbid-
ity.4,5 Data from a national study in the UK showed an
increased risk of both sickle-related complications (acute pain,
acute chest syndrome) and pregnancy-related complications
[hypertension, venous thromboembolism (VTE) and urinary
tract infections].4 A retrospective study has shown that preg-
nancy-related VTE in women with SCD appears to be 15–5
times greater than in the general population.6 Women with
SCD were more likely to require blood transfusion or admis-
sion to the critical care unit. Women with SCD were more
likely to deliver before 37 weeks of gestation and the babies
were more likely to have a reduced birth weight. Whilst
most of these complications were more common in women
with HbSS than HbSC, both groups of women experienced
an increased risk of complications. A systematic review and
meta-analysis of studies in pregnancy in SCD confirmed
these findings showing significant increases in maternal mor-
tality, pre-eclampsia, stillbirth, preterm delivery and infants
that are small for gestational age.5 Meta-regression demon-
strated that increased relative risks were associated with
genotype (HbSS versus HbSC) and low gross national
income.
Although women with HbSC experience fewer adverse
outcomes than women with HbSS, they are still susceptible
to increased painful crises during pregnancy, fetal growth
restriction, antenatal hospital admission and postpartum
infection4,7,8 and these women should have the same level of
vigilance and care as for those with HbSS. There are fewer
data on pregnancy outcomes in women with HbS/bthalas-
saemia, HbSD, HbSE or HbSOArab, but anecdotal evidence
indicates that these too should be similarly monitored and
treated.
Preconception care
Discussion of pregnancy and conception should be embed-
ded into routine care for women with SCD and be part of
the comprehensive annual review (at least) from young
adulthood onwards9 and this should begin in paediatric clin-
ics where appropriate. This should include discussion of
reproductive options, partner screening, optimisation of
health prior to conception, preconception folic acid supple-
mentation and review of teratogenic medications. Preconcep-
tion clinics should be available and accessible.
Genetic screening
Women with SCD who have a partner who is a carrier of a
b globin variant (e.g., HbS, HbC, b thalassaemia) will have a
risk of up to 50% in each pregnancy of having a child with a
sickling disorder. Women with SCD should be counselled
about their reproductive options (non-intervention, prenatal
diagnosis or PGD) by an appropriately trained professional
and this should be clearly documented.
Women are often not aware of the possibility of PGD and
hence do not have the opportunity to consider or participate
in this. A review conducted in a London tertiary referral cen-
tre showed that 60 at-risk couples referred over a five-year
period, over all having 74 cycles of PGD, had a live birth rate
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of 63% per couple.10 This was much higher than the previ-
ously reported 17% live birth rate.11 This paper noted that
there were significant barriers to referral, and a separate sur-
vey of parents of children with SCD found that only 41%
had been aware of PGD prior to pregnancy.12 Care givers
should ensure that discussion of PGD and relevant referrals
take place in a timely fashion.
Recommendations
 As part of the annual review, all women with SCD
should be encouraged to engage with partner testing
prior to embarking on pregnancy (1C).
 High-risk couples should be counselled prior to preg-
nancy about their reproductive options: non-interven-
tion, prenatal diagnosis or pre-implantation genetic
diagnosis (1C).
Preconception comprehensive review of complications
A comprehensive annual review is part of recommended rou-
tine care; discussion of reproduction, pregnancy and contra-
ceptive options and review of chronic complications should
be part of this annual review. The outcomes of the most
recent annual review should be assessed in any woman who
is actively planning pregnancy; investigations of particular
importance preconceptually include assessment of renal dys-
function and cardiopulmonary disease. Renal complications
occur in up to 60% of those with SCD during their lifetimes
and are characterised by glomerular hyper-filtration and
microalbuminuria from young adulthood with the develop-
ment of proteinuria and chronic kidney disease in later
years.13
Prior to pregnancy, women should have blood pressure
monitoring and screening with creatinine and urinary pro-
tein (albumin:creatinine or protein:creatinine ratio). Women
with abnormalities in renal function or proteinuria (protein:
creatinine ratio >50 mg protein/mmol creatinine) should be
investigated to exclude non-sickle causes. Anti-hypertensive
treatment should be considered in women with a persistently
raised blood pressure of >130/80 mm Hg.14 Choice of anti-
hypertensive medication should follow the NICE guidance.15
Pulmonary hypertension, ventricular diastolic dysfunction
and early cardiac death are all increased in SCD and Doppler
echocardiography has been used as a non-invasive tool for
initial evaluation and screening for PH. A raised tricuspid
regurgitant jet velocity (TRV) is associated with increased
mortality and increased risk of PH.16 A small single-centre
study has shown that 33% of pregnant women had a raised
TRV, but this was not associated with poor outcomes.17
Women planning pregnancy should have screening with
echocardiography if this has not been performed in the pre-
vious year and at any time if they have symptoms suggestive
of PH.
Other significant previous medical history should also be
reviewed, for example, history of auto-immune disease as
this may need additional specialist clinical review.
Other complications of SCD that merit screening and
optimisation prior to embarking on pregnancy are sum-
marised in Table II.
Recommendations
 Pregnancy and conception should be discussed with
women of child-bearing age with SCD as part of their
annual review (1C).
 Women should be reviewed by a specialist prior to
conception to ensure optimisation of health and
screening for disease complications (1C).
 Preconception clinics should be available and accessi-
ble (1C).
Preconception medication review
A thorough review of medications should be performed prior
to conception. Folic acid is recommended for patients with
SCD in view of their haemolytic anaemia that puts them at
increased risk of folate deficiency.18 Folic acid is also recom-
mended in all pregnant women to prevent neural tube
defects and should be commenced preconceptually.19 There-
fore, folic acid 5 mg daily should be prescribed when plan-
ning pregnancy and during pregnancy both to reduce the
risk of neural tube defect and to also compensate for the
increased demand during pregnancy.
Vitamin D deficiency is common in patients with SCD
and regular monitoring and supplementation for deficient
patients are recommended outside pregnancy. Vitamin D
supplementation is recommended for all pregnant and
breastfeeding women in the UK.20 Pregnant women with
SCD should be prescribed vitamin D as per national recom-
mendations for pregnancy20 and it may be helpful to moni-
tor vitamin D levels to ensure adequate supplementation.
Patients with SCD are hyposplenic and are at risk of infec-
tion, in particular from encapsulated bacteria such as Neisse-
ria meningitides, Streptococcus pneumonia and Haemophilus
influenzae. Penicillin prophylaxis is of benefit in young chil-
dren with SCD, but there is no randomised trial evidence in
pregnant women. In view of their hyposplenism and
increased risk of pneumonia, pregnant women with SCD
should continue penicillin prophylaxis, or start this if they
are not already taking it. Vaccination status should also be
reviewed and updated as per national recommendations and
this should include annual influenza vaccination and pneu-
mococcal vaccination if this has not been given within the
previous five years.9
The optimal analgesics to use during pregnancy should be
discussed with women as part of their pain management
plan. Paracetamol and codeine-containing analgesics can be
Guideline
982 ª 2021 The Authors. British Journal of Haematology published by British Society for Haematology
and John Wiley & Sons Ltd. British Journal of Haematology, 2021, 194, 980–995
offered during pregnancy as first-line agents.21,22 If these are
not effective, non-steroidal anti-inflammatory drugs
(NSAIDs) should only be used with caution before 12 weeks
and avoided after 31 weeks of gestation owing to concerns
regarding the risk of premature closure of the patent duc-
tus.21 Opioid intake should be assessed, with referral to a
chronic pain team if needed.
As part of standard care potentially teratogenic medica-
tions should be reviewed and particular attention should be
paid to those that are commonly used in SCD including
angiotensin-converting enzyme inhibitors (ACEi) or angio-
tensin II receptors blockers (ARBs) for renal dysfunction,
hydroxycarbamide and iron chelators.
The recent Renal Association Guidelines (2019) recom-
mend that women with chronic kidney disease who are tak-
ing ACEi have a plan for discontinuation/conversion guided
by the strength of indication for renin–angiotensin blockade
and the likelihood of early pregnancy confirmation and that
ARBs are discontinued in advance of pregnancy.21,23 In these
women renal function and proteinuria should be carefully
monitored at least monthly throughout pregnancy.
Many women will be taking hydroxycarbamide prior to
pregnancy as this has been shown to decrease the incidence
of acute painful crisis and acute chest syndrome in individu-
als with severe clinical manifestations of SCD and is the only
currently licensed treatment for SCD in the UK.24 Hydroxy-
carbamide is teratogenic in animals and its use in pregnancy
has been discussed in a previous BSH guideline.25 This
advises stopping hydroxycarbamide preconceptually in female
patients. If women are taking hydroxycarbamide due to
frequent and severe sickle pain episodes, treatment with reg-
ular red cell erythrocytapheresis should be discussed as an
alternative.
If women do become pregnant whilst taking hydroxycar-
bamide, it should be stopped as soon as possible. There are
reports in the literature of women receiving hydroxycarbamide
in pregnancy both for SCD and for other indications and some
of these have continued it throughout pregnancy without
adverse effects on the baby.26–29 Concerns have been raised that
for women with severe phenotype disease and no other treat-
ment options, the risks of stopping hydroxycarbamide (which
include increased risk of pain crises, acute chest syndrome and
worsening anaemia) may outweigh the risks of continuing
hydroxycarbamide. This is particularly true for women who are
not able to receive blood transfusion because of multiple red cell
alloantibodies or previous severe delayed haemolytic transfusion
reactions. For these women, we recommend a discussion
between the haematologist, the obstetrician and the woman prior
to pregnancy to provide her with information about the risks
and benefits of continuing hydroxycarbamide therapy through-
out pregnancy to aid patient-led decision-making. Referral to the
fetal medical unit for additional detailed ultrasound scanning for
fetal abnormalities may be considered, although the reliability in
detecting hydroxycarbamide-induced abnormalities is uncer-
tain.30 A clinical trial is currently collecting retrospective data on
hydroxycarbamide exposure during pregnancy [Hydroxyurea
Exposure Limiting Pregnancy and Follow-up Lactation (HELP-
FUL): NCT04093986].
Iron chelators are not recommended during pregnancy
due to a lack of safety data so they should be regarded as
potentially teratogenic in the first trimester and should be
stopped when a woman is trying to conceive. Women with
iron overload should be carefully assessed with liver and car-
diac magnetic resonance imaging prior to conception to
highlight those at high risks of iron-related complications. If
there is evidence of iron overload, this should be treated
prior to conception. Cardiac iron overload is unusual in
SCD, but if it occurs women should be encouraged to rigor-
ously chelate prior to conception and third-trimester desfer-
rioxamine can be considered.
New medications including voxelotor, crizanlizumab and
glutamine are not approved for use during pregnancy and
should be stopped prior to conception or when pregnancy is
confirmed if unplanned. Although these drugs are not
approved for use in the UK at the time of publication they
may be approved at some point and women may have been
prescribed these drugs from overseas.
Recommendations
 Folic acid (5 mg daily) should be given from before
conception and throughout pregnancy (1A).
 Women should be given vitamin D as per national
recommendations for all pregnant women (1C).
 Daily antibiotic prophylaxis is recommended (2B).
 Vaccinations should be kept updated as per national
recommendations for SCD and should include flu vac-
cination (1B).
Table II. Preconception review of chronic sickle complications.
Chronic complication Action to be taken
Renal disease and
hypertension




Echocardiography if not performed
within 1 year or if symptomatic.
Abnormalities should be discussed with
a cardiologist
Chronic lung disease Oxygen saturations on all women. Sleep
studies and pulmonary function tests if
indicated
Avascular necrosis Review hip complications which may
worsen during pregnancy
Stroke If history of previous stroke consider role
of transfusion during pregnancy if not
already receiving this
Chronic pain Women on long-term opioids should be
referred to a chronic pain clinic for
assessment and managed by pain specialist
during pregnancy
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 When attempting to conceive ARBs should be stopped
and there should be a plan for stopping/converting
ACEi (1C).
 Hydroxycarbamide should be discontinued when
attempting to conceive unless the woman is consid-
ered to be at high risk of serious complications relat-
ing to SCD and blood transfusion is not feasible (2C).




It is essential that any woman who has a potentially affected
infant (i.e. whose partner is a carrier or is affected by a sig-
nificant haemoglobinopathy) is aware of this and receives
appropriate counselling. Partner status and subsequent coun-
selling should be clearly documented. Further information
can be obtained on the NHS Sickle Cell & Thalassaemia
Screening Programme website which includes information
about the laboratories that can perform prenatal diagnostic
testing.31 The objective of the screening programme is to
ensure that screening tests are offered by 8–10 weeks of preg-
nancy by primary care or maternity services, so that early
prenatal diagnosis can be offered.
Prenatal diagnosis (by chorionic villus sampling or amnio-
centesis) should be offered as early as possible in pregnancy
to ensure early access to termination of an affected preg-
nancy if requested. Prenatal diagnosis can be performed from
11 weeks of gestation and is associated with a low risk of
miscarriage (~1%). Studies are ongoing using non-invasive
prenatal diagnosis via detection of cell-free fetal DNA in the
maternal circulation, but this approach is not yet available
outside research studies.32 Non-invasive testing would
increase the uptake of prenatal testing, though this needs to
be balanced against concerns that non-invasive testing
puts couples under increased pressure to have prenatal
intervention.33
Recommendations
 If the woman has not been seen preconceptually, she
should be offered partner testing (1B).
 If the partner is a carrier, counselling regarding the
potential for an affected fetus should take place in the
first trimester to enable prenatal diagnosis and if an
affected fetus is identified the option of termination
should be offered (1B).
Maternal health
Many women become pregnant without preconception care.
Therefore, all of the actions outlined in the section on
preconception care including vaccinations, review of medica-
tions, assessment for organ damage, red cell alloantibodies
and iron status, should take place as early as possible during
pregnancy. Flu vaccine should be given but live attenuated
vaccines should be deferred until after delivery.
Thereafter, the mainstay of antenatal care is monitoring
for and prevention of general and SCD-specific complica-
tions. Guidance on routine antenatal care for the healthy
pregnant woman is provided by NICE CG 6234 Prevention
of SCD-specific complications necessitates multidisciplinary
care involving obstetricians, midwives and Specialised Hae-
moglobinopathy Teams. Good communication between
health professionals is key to patient safety and hospital (or
network) protocols for transfusion indications and early
detection and management of SCD complications including
infection, acute pain and management of labour should be
available.
The frequency of routine appointments will depend on
medical progress and the presence of complications but a
reasonable guide is once per month, for clinical assessment,
counselling, blood pressure measurement, blood tests and
urinalysis to identify asymptomatic bacteriuria.5,35 These are
summarised in Table III.
At each appointment, opportunities should be offered for
giving information and education regarding crisis prevention
measures such as rest, warmth and avoidance of dehydration
and infections. The woman’s housing and work circum-
stances should be reviewed, and interventions that may
reduce the potential provocation of acute crises (e.g.,
improved heating, allowance for increased hospital visits)
should be encouraged. Compliance with prescribed medica-
tions such as folic acid and prophylactic antibiotics should
be ensured. NSAIDs should be used with caution before
12 weeks and avoided after 31 weeks of gestation owing to
concerns regarding premature closure of the patent ductus.
Iron supplementation should be given to women with pro-
ven iron deficiency (serum ferritin <30 lg/l); it should not
be given empirically as for anaemic women without
haemoglobinopathy.36
Hyperemesis gravidarum can lead to dehydration and
sickle cell crisis and women with persistent vomiting should
be advised to seek medical advice early. They should be kept
hydrated and consideration given to hospital admission and
thromboprophylaxis. Multiple gestation in women with SCD
substantially increases the risk of pre-eclampia, hypertension,
acute pain episodes and acute anaemic events; therefore these
pregnancies require close attention and increased monitor-
ing.
Pregnancy-induced hypertension
Women with SCD have an increased risk of pregnancy-in-
duced hypertension and pre-eclampsia.4,5,37 Aspirin prophy-
laxis is recommended at 75–150 mg daily from 12 weeks of
gestation for women at high risk of pre-eclampsia,15,38 unless
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Table III. Specific antenatal care for women with SCD32.
Appointment Care for women with SCD during pregnancy
First appointment (primary care or hospital appointment) Offer general health information, advice and support
Offer partner testing if not already done
Review partner results and discuss PND if appropriate
Clinical history to assess SCD complications
Assess retinal, renal and cardiac complications as necessary
Review medications
Ensure women are taking 5 mg folic acid and prophylactic
antibiotics and discuss vaccinations
Document baseline oxygen saturations and blood pressure
Send MSU for culture
Booking appointment: see multidisciplinary team plus
midwife with experience in high-risk obstetrics if possible
Information, education and advice about SCD and pregnancy
Review partner results and discuss PND if appropriate
Baseline full blood count, renal function test, urine
protein/creatinine
ratio, liver function test, ferritin and group and screen
Extended red cell phenotype if not previously performed
Prescribe 75–150 mg aspirin
Start vitamin D prophylaxis if not already on this
Risk assessment for VTE and consider thromboprophylaxis
Review individual pain management plan
10–14 weeks First-trimester ultrasound scan
16 weeks: see midwife plus multidisciplinary review Routine as per NICE; repeat MSU
Multidisciplinary review (consultant obstetrician and haematologist)
20 weeks: see midwife plus multidisciplinary review Detailed ultrasound as per NICE antenatal guideline
Repeat FBC and MSU
24 weeks: see multidisciplinary team Ultrasound monitoring of fetal growth and amniotic fluid volume
Repeat FBC and MSU
26 weeks: see midwife Routine check including blood pressure and urinalysis
28 weeks: see multidisciplinary team Ultrasound monitoring of fetal growth and amniotic fluid volume
Repeat MSU
Repeat FBC and group and antibody screen
Review VTE risk factors and consider thromboprophylaxis
30 weeks: see midwife and offer antenatal classes Routine check including blood pressure and urinalysis
32 weeks: see multidisciplinary team Routine check
Ultrasound monitoring of fetal growth and amniotic fluid volume
Repeat MSU and FBC
Offer anaesthetic assessment at 32 weeks or earlier if indicated
34 weeks: see midwife Routine check including blood pressure and urinalysis
36 weeks: see multidisciplinary team Routine check
Repeat MSU and FBC
Ultrasound monitoring of fetal growth and amniotic fluid volume
Consider whether to stop aspirin prior to delivery
Offer information and advice about:
 Timing, mode and management of the birth
 Care of baby after birth
 Analgesia and anaesthesia
38 weeks: see midwife and obstetrician Routine check
Discuss timing and mode of delivery
39 weeks: see midwife Routine check and review delivery plan
40 weeks: see obstetrician Routine check and offer fetal monitoring if the woman declines
delivery by 40 weeks of gestation
FBC, full blood count; MSU, midstream urine; NICE, National Institute for Health and Clinical Excellence; PND, prenatal diagnosis; SCD, sickle
cell disease; VTE, venous thromboembolism.
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they have aspirin sensitivity. Although there is no specific
evidence that aspirin decreases the risk of pre-eclampsia in
women with SCD, in view of their increased risk we recom-
mend that women with SCD and no contraindications
should be offered aspirin prophylaxis from 12 weeks.15
Recent evidence suggests that aspirin may increase the risk of
postpartum haemorrhage.39 so should be stopped at
36 weeks.
Close monitoring for pre-eclampsia is part of antenatal
care for all women and blood pressure and the presence of
proteinuria should be assessed at each visit. Women with
pre-existing proteinuria or known renal impairment will
require more frequent monitoring and should be discussed
with a multidisciplinary high-risk pregnancy team.23 Women
with SCD often have a low blood pressure, so an upward
trend in blood pressure, even if modest, should be monitored
carefully. A target blood pressure of <130/80 mm Hg should
be used, based on recent American Society of Hematology
(ASH) recommendations for all patients with SCD.14 This is
lower than recommendations for women without SCD.15 In
women with neurological symptoms it is important to distin-
guish pre-eclampsia/eclampsia from the neurological compli-
cations of SCD.
Recommendations
 A full assessment, as for preconception care, should
be repeated as early as possible in the antenatal per-
iod, including review of vaccinations and medications,
organ damage and red cell alloantibodies (1B).
 Antenatal care should be provided by a multidisci-
plinary team including an obstetrician and midwife
with experience of high-risk antenatal care and a
haematologist with links to a Specialised Hae-
moglobinopathy Team (1C).
 Regular antenatal appointments for women with SCD
should provide routine antenatal care as well as care
specifically for women with SCD (1C).
 Women with persistent vomiting should be advised to
seek medical advice early (1C).
 Women should be reminded to take daily folic acid
(5 mg) and prophylactic antibiotics (if not contraindi-
cated) and avoid drugs that are unsafe in pregnancy
(1A).
 Iron supplementation should be given if there is labo-
ratory evidence of iron deficiency (1B).
 Women with SCD should be considered for low-dose
aspirin 75–150 mg once daily from 12 weeks of gesta-
tion in an effort to reduce the risk of developing pre-
eclampsia and should be monitored for blood pressure
rises and proteinuria (1B).
 Aspirin prescription should be reviewed at 36 weeks
of gestation to consider stopping prior to delivery
(2C).
Scheduled ultrasound scanning
Standard ultrasound scanning should be performed as per
the NICE guidelines.34 A number of studies suggest an
increased risk of fetal anomalies and babies that are small for
gestational age in the offspring of women with SCD.37
Third-trimester growth scans should be undertaken for early
detection of fetal growth restriction to aid appropriate timing
of delivery and to reduce perinatal mortality and morbidity
in view of the four times increased risk of stillbirth.40 If preg-
nancy-associated plasma protein A (PAPP-A) levels are per-
formed in the first trimester and the value is <05 multiple
of the median then consider performing more frequent scans
after 20 weeks.41
Recommendations
 Women should be offered serial fetal biometry scans
(growth scans) every four weeks from 24 weeks of ges-
tation (1C).
Blood transfusion during pregnancy
Transfusion has been used in pregnant women with SCD to
correct severe anaemia and reduce sickle-related complica-
tions. It may also reduce pregnancy complications by reduc-
ing the extent of sickling in the maternal and placental
circulation and therefore may improve blood flow and oxy-
gen supply to the fetus. These benefits must be weighed up
against the side effects of transfusion including the risk of
alloimmunisation and risk of delayed haemolytic transfusion
reactions. The type of blood selected for transfusion of
women with SCD should be cytomegalovirus (CMV)-nega-
tive, HbS-negative and extended Rh- and Kell-matched in
line with previous BSH recommendations.42
A full transfusion history should be taken from the patient
at the booking appointment or first obstetric/haematology
appointment and should include communication with the
transfusion laboratory and national transfusion database to
ensure there are no historical alloantibodies. Patients with
historic alloantibodies should be referred to the fetal red cell
antibody clinic or screening programme for haemolytic dis-
ease of the newborn for monitoring of antibody titres.
A key question in the management of pregnant women
with SCD regards the best approach to blood transfusion
during pregnancy. One approach is to give blood only if
required by the clinical situation, for example for acute anae-
mia or other acute complications. The other approach is to
give blood prophylactically throughout pregnancy; if this
approach is used then further questions include whether sim-
ple or exchange transfusion should be used, at what gestation
transfusion therapy should be started and is there a target
Hb or HbS% that should be used. This has been discussed in
a previous BSH guideline and a recent ASH guideline.43,44
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There is currently insufficient evidence to recommend
prophylactic transfusion over standard care (transfusion as
required) and whilst there is some evidence that prophylactic
transfusion will reduce vaso-occlusive pain during pregnancy
it is not clear if the benefits of transfusion will outweigh the
risks of transfusion (e.g., alloimmunisation). The recent ASH
guidelines44 concluded that there was insufficient evidence to
recommend a strategy of prophylactic transfusion rather than
standard care. A phase 2 clinical trial is currently investigat-
ing the role of serial prophylactic exchange blood transfusion
in pregnant women with SCD (TAPS-2).45
In one randomised trial, including 72 women and pub-
lished in the 1980s44 women received standard care or pro-
phylactic transfusion with simple or partial exchange
transfusion to achieve Hb 100–110 g/l and HbS% < 35%. In
the standard care arm, 44% of women required transfusion.
There was a significant reduction in vaso-occlusive crises in
the prophylactic transfusion arm [relative risk (RR) 028,
95% confidence interval (CI) 012–067] but no clear differ-
ences in other outcomes (maternal mortality, perinatal mor-
tality or severe maternal morbidity) although this may be
explained by the small numbers included in the trial. There
was no harm identified from the transfusions. A Cochrane
review47 did not find any additional randomised trials and
concluded that there were no clear clinical benefits of prophy-
lactic transfusion over standard care. There have been numer-
ous observational trials reporting on outcomes of
prophylactic transfusion in pregnancy and a meta-analysis has
reported on the previous randomised clinical trial and addi-
tional 11 cohort studies involving 1 291 participants.48 This
meta-analysis demonstrated that prophylactic transfusion was
associated with a reduction in maternal mortality, vaso-occlu-
sive crises, pulmonary complications, pyelonephritis, perinatal
mortality, neonatal death and preterm birth. There was no
difference in pulmonary infection, acute chest syndrome, uri-
nary tract infections, pre-eclampsia, intrauterine fetal demise,
infants that are small for gestational age or have a low birth
weight. The event rates were low for most of the outcomes
and they concluded that prophylactic transfusion may posi-
tively impact on severe maternal and neonatal outcomes but
the evidence comes from a small number of studies.
There has been a further paper looking at outcomes of
women with HbSC and comparing 10 women receiving pro-
phylactic exchange transfusion with 14 women receiving
transfusion on demand or no transfusion but numbers were
small and selection methods were biased so it is not possible
to reach conclusions about the role of prophylactic transfu-
sion in women with HbSC.49
The risks and benefits of prophylactic transfusion during
pregnancy should be discussed with the patient, haematolo-
gist and obstetrician in early pregnancy and factors to be
considered will include:
1. Genotype (HbSS more likely to benefit than HbSC).
2. Phenotype (severe disease phenotype more likely to benefit).
3. Previous obstetric history (women with a history of previ-
ous sickle complications in pregnancy may be more likely
to benefit).
4. Twin pregnancy may be more likely to benefit (expert
opinion due to adverse outcomes in twin pregnancies).
5. Alloimmunisation (women with a history of multiple red
cell alloantibodies or previous delayed haemolytic transfu-
sion reaction are at increased risk of transfusion-related
complications).
Women who are already on long-term transfusion ther-
apy should continue on this during pregnancy at the same
frequency. Women on hydroxycarbamide will be advised
to stop this prior to conception and prophylactic transfu-
sion should be considered if they experience a worsening
of their sickle symptoms once they stop hydroxycarbamide
or if they have a very severe prehydroxycarbamide pheno-
type.
If the benefits of prophylactic transfusion are not
thought to outweigh the risks, then standard care is to give
transfusion on demand, when clinically indicated. There is
little evidence to indicate what target Hb or HbS% should
be used for optimal care and most evidence comes from
the care of non-pregnant patients with SCD. The ran-
domised trial of transfusion described above46 used an Hb
value of <60 g/l as an indication for simple transfusion and
this level was used in previous RCOG guidance.1 Many
clinicians would aim for a higher Hb value during preg-
nancy although this will depend on baseline Hb and symp-
toms of anaemia. Women with severe sickle complications
(e.g., acute chest syndrome, stroke or intractable pain)
should be treated with transfusion as recommended in non-
pregnant patients with SCD.43,50
There is no evidence about the optimal Hb level or HbS%
prior to caesarean delivery. A randomised trial looking at
elective surgery in non-pregnant patients with HbSS showed
that pre-operative transfusion to Hb > 90 g/l was associated
with reduced postoperative sickle complications, particularly
acute chest syndrome.51 Caesarean section was not included
in this trial and the main complications were probably due
to general anaesthesia. Women with marked anaemia (<70 g/
l) may benefit from pre-operative transfusion prior to cae-
sarean section.
Recommendations (adapted from Refs.42,43)
 If transfusion is needed, pregnant women with SCD
should be given ABO-compatible, extended Rh- and
Kell-matched, CMV-negative units. If there are clini-
cally significant red cell antibodies (current or histori-
cal) then the red cells selected should be negative for
the corresponding antigens (1C).
 The risks and benefits of prophylactic transfusion dur-
ing pregnancy should be discussed with the patients
as part of the haematology/obstetric consultation (2C).
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 Prophylactic transfusion is not routinely recom-
mended for sickle pregnancy, but should be consid-
ered for women with:
a Previous or current medical, obstetric or fetal prob-
lems, related to SCD. (2C).
b Women previously on hydroxycarbamide due to sev-
ere disease (2C).
c Multiple pregnancy (2C).
 Women receiving long-term transfusions for stroke
prevention or for the amelioration of severe sickle
complications should continue with regular transfu-
sions throughout pregnancy (1B).
 Transfusion may be required in women with worsen-
ing anaemia (1B).
 Transfusion should be considered for those with acute
SCD complications (e.g., acute chest syndrome, stroke)
(1B).
Management of acute pain episodes during pregnancy
Pregnancy is associated with an increased incidence of acute
painful crises,52–56 in both HbSS and to a lesser extent HbSC
disease.7 In a prospective UK study, acute pain was the most
common complication, affecting 57% of pregnant women
with SCD. Severe or extremely severe crises (requiring hospi-
tal attendance or admission) occurred in 176% of women
with HbSS and 91% of women with HbSC (P = 023). Post-
natal painful crises were also significantly higher in the HbSS
women, occurring in 216% of HbSS and 23% of HbSC
women (P = 001).4
There are a number of possible reasons for the increased
incidence of crisis including increased physical and psycho-
logical stress; dehydration, particularly in early pregnancy
when nausea and vomiting are common; worsening anaemia,
which is common in pregnancy, related to increased iron
requirements and red cell turnover; the pro-coagulant state
in pregnancy predisposing to vaso-occlusive disease; and the
increased risk of infection, for example, urinary infection or
influenza, which can precipitate a sickle crisis. Birth, whether
by vaginal delivery or caesarean section, is a profound physi-
ological challenge and can increase the risks of dehydration,
hypoxia, anaemia, overexertion and significant metabolic
derangement, which can all lead to a higher incidence of cri-
sis. Pregnant women with SCD may present with non-sickle
causes of acute pain such as placental abruption or appen-
dicitis. A careful history is essential to determine whether the
pain is typical for vaso-occlusive pain and if not alternative
aetiologies should be explored.
All pregnant women should have a prospective pain man-
agement plan for use in the event of a potential crisis that
should have been developed and discussed with the multidis-
ciplinary team (MDT) and the woman and shared with all
healthcare providers involved with her care including her
general practitioner and her community midwife. This
should be discussed at her first multidisciplinary clinic
appointment and reviewed at subsequent appointments.
There should be a low threshold for referring a woman to
secondary care and all women with pain that does not settle
with simple analgesia, who are febrile, have atypical pain or
chest pain or symptoms of shortness of breath should be
referred to hospital.
There are no randomised controlled trials examining the
management of painful crisis in pregnant women with SCD, so
treatment of acute pain in pregnant women should follow
national recommendations applicable to non-pregnant women
with modifications to account for evidence of safety of specific
analgesics for the fetus. Mild pain may be managed in the com-
munity with rest, oral fluids and paracetamol or weak opioids
(such as co-dydramol, co-codamol or dihydrocodeine). NSAIDs
should be used with caution in the first trimester and avoided
after 31 weeks of gestation due to the risk of premature closure
of the patent ductus.21,22,57 If a woman needs strong opiate ther-
apy, she will need to be admitted to the hospital. The NICE
guidelines for the management of acute crisis advocate that
analgesia be given within 30 min of arrival in hospital after a
rapid initial assessment and the pain should be controlled
within 60 min of starting analgesia.58 There is no evidence to
suggest pregnant women should be treated differently.
For severe pain, morphine, diamorphine or oxycodone
can be given by the oral, subcutaneous or intravenous route,
depending on the woman’s preference and local expertise.
Pethidine should be avoided because of the risk of toxicity
and pethidine-associated seizures in patients with SCD.
On presentation, a woman with sickle crisis should be
assessed rapidly for medical complications and precipitating
factors requiring intervention. A full set of observations,
using a modified obstetric early warning chart, including sys-
tolic and diastolic blood pressure, pulse, respiratory rate,
temperature, oxygen saturation and pain score should be
recorded and repeated every 1–2 h.58 With analgesia admin-
istration, assessments of pain score, sedation score and respi-
ratory rate should be monitored initially at 20-min intervals.
Women should ideally be cared for in an environment with
experienced nurses/midwives with training in looking after
pregnant women with SCD. Depending on local expertise
and the gestation of the woman and the severity of her con-
dition, it may be appropriate to manage her on a medical
ward, a haematology ward, an obstetric ward or in a level 2
or 3 critical care setting. Senior obstetricians, haematologists,
obstetric anaesthetists, obstetric physicians, specialist nurses
and midwives should make up the MDT and care should be
coordinated and planned by this group and discussed with
the woman and her family.
Fluid status should be assessed and documented carefully.
Dehydration should be avoided, and intravenous (IV) fluids
may be required to maintain adequate hydration. Fluid status
and IV fluid prescription should be reviewed at least 12-
hourly, especially in a woman with SCD-related renal disease
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or with suspected pre-eclampsia as fluid overload is a poten-
tial risk.
Oxygen saturations should be monitored and if oxygen
saturation falls below the woman’s baseline or below 95%
urgent medical review should be requested, due to the risk of
acute chest syndrome and pulmonary embolism (PE), and
facial oxygen should be prescribed. There should be early
recourse to intensive care if satisfactory oxygen saturation
cannot be maintained with oxygen via face mask or nasal
cannula. Women with back or chest pain should be offered
an incentive spirometer.
The woman should be assessed for infection and urine
culture and microscopy performed. A chest X-ray should
be performed if the woman has abnormalities on chest
examination or is hypoxic. Antibiotics as per the local
pregnancy-specific guideline should be prescribed, if the
woman is febrile or there is a high clinical suspicion of
infection. White blood cell counts are often raised in preg-
nant women and in SCD and alone, do not necessarily
indicate infection.59
Thromboprophylaxis should be prescribed for women
with SCD who are admitted to hospital with painful crises,
unless there is a contraindication.60 Other adjuvants may be
required to treat the adverse effects of opiates, such as anti-
histamines to treat itching or laxatives to prevent opiate-in-
duced constipation, and anti-emetics may be required. As the
painful crisis resolves, most women are able to reduce their
opiate requirement rapidly, but this should be guided by the
woman’s previous experience.
In severely unwell woman, an accurate identification of
the gestation of the fetus is required. If before the threshold
for viability (approximately 24 weeks and 500 g), additional
fetal monitoring is not needed. From 24 to 28 weeks, fetal
well-being should be monitored by ultrasound scanning.
After 28 weeks daily continuous fetal monitoring should be
performed in addition to ultrasound scanning (if not per-
formed in the last week).
Recommendations
 Pregnant women with SCD should have an agreed
pain management plan for the treatment of acute
painful crisis (1D).
 If pregnant women are admitted with acute pain crises
they should be looked after by the MDT (1D).
 The NICE guidelines58 on the management of acute
painful episodes should be followed (1B).
 NSAIDs should be used with caution in the first tri-
mester and avoided after 31 weeks of gestation (2C).
 Fluid and oxygen balance should be monitored regu-
larly in women admitted with sickle pain crisis (1D).
 Women with SCD should be prescribed prophylactic
low-molecular-weight heparin during any antenatal
hospital admission (1B).
Management of acute chest syndrome
Acute chest syndrome is an important complication of SCD
affecting up to 10% of pregnant women with SCD.4 It is
characterised by fever and/or respiratory symptoms and a
new pulmonary infiltrate on chest X-ray. Patients should be
monitored for this complication throughout their hospital
stay and all hospitals should have a guideline that includes
the treatment pathway.50 Essential investigations for diagno-
sis and prognosis include chest X-ray and full blood count.
Arterial blood gas analysis should be considered in adults
with low oxygen saturations as severe hypoxia is a useful pre-
dictor of severity and helps guide treatment. The main differ-
ential diagnosis is PE which should be considered in patients
with a normal chest examination and chest X-ray. Aetiology
is multifactorial and includes infection so careful investiga-
tion for infective causes should be undertaken including
blood cultures, sputum for microscopy and culture and spu-
tum and nasopharyngeal aspiration for viral testing.
Basic management will include prompt pain relief, incen-
tive spirometry and treatment of bacterial or viral infection.
Blood transfusion should be considered early in the hypoxic
patient. A simple (top-up) transfusion may suffice in early or
less severe disease but exchange transfusion will be necessary
if there are features of clinical severity or a lack of response
to simple transfusion.
The critical care team should be involved in the care of
any patients with severe clinical features or in a deteriorating
patient to consider non-invasive or invasive ventilation. Fol-
lowing an episode of acute chest syndrome requiring transfu-
sion, the patient should be offered regular prophylactic blood
transfusion throughout the remainder of pregnancy.
Recommendations (adapted from Ref.50)
 Patients with SCD can present with acute chest syn-
drome (ACS) or it may develop after the onset of sev-
ere pain. Therefore vigilance should be maintained
throughout hospital admission (1B).
 All hospitals should have a treatment pathway for
ACS which should include a referral pathway to the
high dependency unit or intensive care unit (1B).
 Antibiotics, with cover for atypical organisms, should
be used even if blood cultures and sputum cultures
are negative (1B).
 Simple (‘top-up’) transfusion should be considered
early in the hypoxic patient but exchange transfusion is
necessary if there are severe clinical features or evidence
of progression despite initial simple transfusion (1B).
Management of other acute complications
Acute stroke, both infarctive and haemorrhagic, is associated
with SCD61 and this diagnosis should be considered in any
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woman with SCD who presents with acute neurological
impairment. Acute stroke is a medical emergency and
requires urgent brain imaging and referral to the stroke
physician and haematologist. Rapid exchange blood transfu-
sion can decrease long-term neurological damage. The role
of thrombolysis should be discussed with a stroke physician
and senior obstetrician. In women with neurological signs, it
is important to distinguish cerebrovascular disease due to
SCD from pre-eclampsia/eclampsia.
Acute anaemia in women with SCD may be attributable
to erythrovirus infection (parvovirus B19). Infection with
erythrovirus in SCD causes a red cell maturation arrest
and an aplastic crisis characterised by a reticulocytopenia.
Therefore, a reticulocyte count should be requested in any
woman presenting with an acute anaemia and, if low, may
indicate infection with erythrovirus. Treatment is with
blood transfusion and the woman must be isolated. With
erythrovirus infection there is the added risk of vertical
transmission to the fetus, hence a review by a fetal medi-
cine specialist is indicated to assess fetal anaemia.62,63
Women with SCD can develop anaemia owing to bleeding
or any other causes of anaemia incidental to the SCD.
Rare causes of anaemia in SCD include malaria and, occa-
sionally, splenic sequestration in women with a mild
phenotype.
Recommendations
 Acute stroke should be considered in women present-
ing with acute neurological impairment and requires
urgent consideration of exchange transfusion (1B).
 Acute erythrovirus infection should be considered in
women presenting with acute anaemia (1A).
Management of VTE and thromboprophylaxis
Pregnancy is a well-established risk factor for VTE for
women but this risk is magnified in pregnant women with
SCD.64–68 In a recent meta- analysis the risk of VTE [odds
ratio (OR) 332, 95% CI 97–1134, P < 0001] and deep vein
thrombosis (OR 307, 95% CI 16–5782, P = 002) were
increased when compared to a cohort without SCD.68 The
prevalence of VTE was 35-fold greater in women with com-
plications such as vaso-occlusive crisis, acute chest syndrome
and pneumonia when compared to those without these com-
plications, but was less in those with more severe anaemia.6
In this study 286% and 714% of VTE episodes were identi-
fied as having occurred in the antenatal and postpartum
periods respectively.
SCD is listed as one of the risk factors for thrombosis in
the 2015 RCOG Green-top guideline: Reducing the Risk of
VTE during Pregnancy and the Puerperium.60 This guideline
provides recommendations for risk assessments for thrombo-
prophylaxis and suggests that:
1. All women with SCD should have risk assessments per-
formed in early pregnancy, if admitted to hospital, in the
intrapartum and early postpartum period.
2. Women with SCD should be considered for prophylactic
low-weight heparin (LMWH) from 28 weeks of preg-
nancy until six weeks postpartum and if women have
additional risk factors, prophylaxis should start from the
beginning of pregnancy.
3. Women admitted to hospital with a vaso-occlusive crisis
or for other reasons should be offered LMWH through-
out their admission unless there are contraindications.
Due to the higher incidence of PE in women with co-exis-
tent chest infections or acute chest syndrome6 and the over-
lap in presenting features a high index of suspicion for PE is
required when assessing these patients. Women suspected of
VTE should be managed according to RCOG Green-top
Guideline No. 37b: The Acute Management of Thrombosis
and Embolism during Pregnancy and the Puerperium.69
Recommendations: (adapted from RCOG Guideline
37a60)
 All women with SCD should have risk assessments
performed in early pregnancy, if admitted to hospital,
in the intrapartum and early postpartum period (1C).
 Women with SCD should be considered for prophy-
lactic low-weight heparin (LMWH) from 28 weeks of
pregnancy until six weeks postpartum and if women
have additional risk factors, prophylaxis should start
from the beginning of pregnancy (2B).
 Women admitted to hospital with a vaso-occlusive cri-
sis or for other reasons should be offered LMWH




There are no randomised controlled trials to dictate the
appropriate timing of delivery. Recent systematic review and
meta-analysis5,70 confirm increased perinatal mortality, par-
ticularly during the later stages of pregnancy, in part due to
the complications of SCD. The risks of abruption, unex-
plained stillbirth, pre-eclampsia, peripartum cardiomyopathy
and acute sickle cell crisis are increased and unpredictable. A
prospective birth plan should be made, in consultation with
the woman to include mode of delivery, place of labour,
MDT, positions for labour, analgesia and additional moni-
toring requirements that may be appropriate. Due to the
increased risk of placental insufficiency and pre-eclampsia,
delivery between 38 and 40 weeks is often indicated to pre-
vent late-pregnancy complications and associated adverse
perinatal outcomes.
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Recommendation
 Pregnant women with SCD who have a normally
growing baby should be delivered between 38 and
40 weeks of gestation (2D).
Mode of birth
Whilst older studies questioned vaginal delivery as the opti-
mal mode of delivery for women with SCD, recent studies
reflecting UK practice of supporting vaginal delivery as the
recommended mode of delivery, with the need for the cae-
sarean section based on obstetric indications, report satisfac-
tory outcomes.4,5 Caesarean section increases the woman’s
risk of infection and VTE so elective caesarean birth should
not be advised for women with SCD in the absence of other
risk factors or obstetric indications. Women with SCD are
more at risk of caesarean section because of the increased
obstetric complications such as pre-eclampsia, intra-uterine
growth restriction and the need for earlier delivery.5 Previous
avascular necrosis of the hip can lead to poor hip rotation
and abduction; and in women with recurrent severe crises,
avoiding a long labour may help to minimise the risk of
intrapartum SCD crisis.
Recommendations
 Women with SCD can be offered vaginal delivery and
vaginal birth after previous caesarean (VBAC) if there
are no other contraindications (2D).
 In women who have hip replacements (because of
avascular necrosis) suitable positions for delivery
should be discussed prior to delivery (1D).
Optimal intrapartum care
Good analgesia (with a prospective management plan for
anaesthetics made prior to labour), with avoidance of dehy-
dration, regular monitoring of oxygen saturations and avoid-
ance of a protracted labour, form the mainstay of the
intrapartum management of a woman with SCD. General
anaesthesia carries additional risks beyond the normal obstet-
ric case and should be avoided where possible. Women
should be offered review by an anaesthetist in the third tri-
mester of pregnancy to discuss these issues. Pethidine should
be avoided because of the risk of seizures when administered
to a woman with SCD.
There are no randomised controlled trials regarding the
place of birth for women with SCD but women should be
advised to give birth in hospitals that are able to manage
both the complications of SCD and high-risk pregnancies.
Obstetricians need to be aware of the increased frequency of
sickle cell crisis and ACS in the intrapartum period and of
the increased risk of painful crisis with long labour (>12 h).
This is often secondary to dehydration and in this situation,
the woman should be well hydrated. If labour is progressing,
the labour should be carefully supervised; caesarean section
should be considered if labour is not progressing well and
delivery is not imminent.
During labour, if oral hydration is not tolerated or is
inadequate, intravenous fluids should be administered using
a fluid balance chart to prevent fluid overload. If venous
access is difficult to obtain the woman should be referred
to the anaesthetist. The demand for oxygen is increased
during the intrapartum period and the use of pulse oxime-
try to detect hypoxia in the mother is appropriate during
labour. Arterial blood gas analysis may be considered and
oxygen therapy instituted if oxygen saturation is 94% or
less.
Routine antibiotic prophylaxis in labour is currently not
supported by evidence, but hourly observations of vital signs
should be performed. A raised temperature (over 375C)
requires investigation. The clinician should have a low
threshold to commence broad-spectrum antibiotics.
There are no randomised controlled trials regarding inter-
ventions during labour for women with SCD but close obser-
vation during labour is essential. Continuous electronic fetal
heart rate monitoring is recommended because of the
increased rate of stillbirth, placental abruption and compro-
mised placental reserve.71 Sickle cell crisis in labour should
be treated as per the guidance for antepartum crisis above.
Epidural analgesia is safe and effective and should be
available for women in labour.
Recommendations
 Women with SCD should be advised to give birth in
hospitals that are able to manage both the complica-
tions of SCD and high-risk pregnancies (1D).
 The relevant MDT (senior midwife in charge, senior
obstetrician, anaesthetist and haematologist) should
be informed as soon as labour is confirmed (1D).
 Blood should be cross-matched for delivery if there
are atypical antibodies present (since this may delay
the availability of blood) (1D).
 Women should be kept warm and given adequate fluid
during labour, using a fluid balance chart to avoid
fluid overload (1D).
 Continuous intrapartum electronic fetal heart rate
monitoring is recommended owing to the increased
risk of fetal distress, which may necessitate operative
delivery (1D).
 Women with SCD should be offered anaesthetic
assessment in the third trimester of pregnancy (2D).
 Opiates may be used for analgesia, except for pethi-
dine (1D).
 Regional analgesia is recommended for caesarean sec-
tion (1D).
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It is important for clinicians to remain vigilant postnatally as
the risk of sickle cell crisis remains increased with 21–25% of
women having a crisis post delivery and crisis being more
common following general anaesthesia.5,72 Hydration and
oxygenation should be maintained and early mobilisation
encouraged. Crises should be managed as for non-pregnant
women. NSAIDs are routinely administered in the postpar-
tum period and can be used during breastfeeding. Neonates
and young infants are at risk from the adverse effects of opi-
oids. Codeine should not be given during breastfeeding.
Dihydrocodeine and tramadol and other opioids can be used
but should be at the lowest effective dose, for the shortest
duration and under medical supervision. Infants should be
monitored for sedation, breathing difficulties, constipation,
difficulty feeding and weight gain.
Breastfeeding should be encouraged, as in women without
SCD. If the baby is at high risk of SCD (i.e. the partner is a
carrier, affected or unknown status) early testing for SCD
should be offered. Samples should be sent to laboratories
where there is experience in the routine analysis of SCD in
newborn samples.
Routine care should be provided as per the NICE guide-
line on postnatal care.73 Antithrombotic stockings are recom-
mended in the puerperium.60 Thromboprophylaxis in the
form of LMWH is recommended whilst the pregnant woman
is in hospital and for six weeks post delivery.60
Women should be given appropriate postpartum contra-
ceptive advice, the timing depending on breastfeeding and
the choice of contraception to be used.
Recommendations
 Women should be advised that they have an increased
risk of pain episodes in the postnatal period and pre-
cipitants should be avoided (1D).
 Women should receive thromboprophylaxis with
LMWH for six weeks after delivery (1C).
Contraception advice for women with SCD
Given the health risks of an unintended pregnancy, coun-
selling about contraception is an important component in
the care of women with SCD and appropriate advice should
be conveyed to the woman’s primary care workers. Used cor-
rectly, all hormonal contraceptives have 99% efficacy and the
choice of contraception should be individualised, taking into
account the woman’s preference, lifestyle and ease of compli-
ance.
There is theoretical concern with combined hormonal
contraceptives (CHCs) that the risk of thrombosis or sickle
crisis may be increased. A retrospective study of
1 257 women with SCD, of which 178 (142%) were CHC
users, showed a fourfold increased risk of ischaemic stroke
associated with CHC. However, when adjusted for confound-
ing cardiovascular risk factors such as smoking, there was no
significant difference.74 A systematic review found no effect
of CHCs on the frequency of sickle crises or other adverse
events and no effect on haematological parameters associated
with sickle crises.75 However, whilst evidence remains lim-
ited, the authors’ recommendations are that CHCs should be
used selectively, with risk being mitigated by controlling
other cardiovascular risk factors. The 2019 updated Faculty
of Sexual & Reproductive Healthcare (FSRH) guide classifies
CHCs as category 2, where the advantages outweigh the the-
oretical risks.76
Progesterone-only preparations, such as the progesterone-
only pill, injectable contraceptives and the levonorgestrel
intrauterine system (LNG-IUS) have not been shown to have
detrimental effects77 and indeed there is some evidence of
clinical benefit. An early study showed oral progesterone led
to an 80% reduction in painful episodes.78 Intramuscular
depo-medroxyprogesterone acetate (DMPA) has been found
to reduce painful crises79 and improve laboratory parame-
ters80 suggesting an inhibition of in vivo sickling. Etono-
gestrel sub-dermal implant has been associated with
improved well-being in women with SCD,81 with clinical
improvement paralleled by elevation of F cells.82 With the
LNG-IUS bleeding may be unpredictable for the first few
weeks but most women will see reduced bleeding thereafter.83
The FSRH classifies progesterone-only preparations as cate-
gory 1, unrestricted use.76
The copper intrauterine device is classified as category 2
due to concern about the potential increased risk of blood
loss but it is still considered that the benefits outweigh the
risks. Barrier methods are safe in women with SCD but gen-
erally less effective than other forms of contraception.
Recommendations
 Contraceptive advice should be given and conveyed to
the woman’s primary care team (1D).
 The choice of contraception should be individualised
but methods that eliminate user failure, such as LNG-
IUS and sssntramuscular DMPA are preferred (2B).
 There is some evidence for reduction in sickle pain
associated with progesterone-only preparations (2C).
 CHCs are an option for women with SCD but cardio-
vascular risk factors should be minimised to mitigate
potential risk (2D).
Conclusion
The majority of women with SCD in the UK will reach repro-
ductive age and discussion of reproduction options and
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pregnancy should form part of their annual review. Pregnancy is
a time of increased risk for women with SCD with increased
rates of maternal and fetal complications. Therefore each hospi-
tal should have a protocol for the management of pregnant
women with SCD. This should identify an MDT that has
responsibility for the care of pregnant women with SCD, includ-
ing an obstetrician with expertise in managing high-risk preg-
nancies and a haematologist. Areas with a low prevalence of
SCD should be linked to a specialist centre or haemoglobinopa-
thy co-ordinating centre for shared care arrangements and
shared protocols and all staff involved in maternity care should
receive training in the care of pregnant women with SCD.
The majority of the recommendations in this document
are of low certainty, reflecting the limited knowledge base
and lack of clinical trials in this area and many are based on
expert opinion. As such they are likely to be updated if fur-
ther clinical evidence becomes available. There is a need for
well-designed clinical trials in this area to ascertain optimal
treatment options.
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